

U.S. Food and Drug Administration



Session 3: Nickel Leaching

Moderators: Nicole Ibrahim and Jennifer Goode, FDA

- Objective 1: Discuss the consequences of nickel exposure (30 min)
- Objective 2: Discuss in vitro nickel leach testing (60 min)
- Objective 3: Discuss in vitro/in vivo nickel release correlation (60 min)
- Objective 4: Discuss toxicity associated with levels of nickel exposure (60 min)
- Objective 5: Moving Forward: Identify knowledge gaps (30 min)


Objective 1: Discuss the biological consequences of nickel exposure (30 min)

 General talk on biological response/toxicity of nickel (Kathy Squibb, University of MD; 20 min)


 Discuss the general biological response to/toxicity of nickel (10 min)

Objective 2: Discuss in vitro nickel leach testing (60 min)

HW: Do you perform in vitro nickel leach testing?



HW: If so, when.....




N=8*


Categories with no responses:

- •All Metallic Devices
- •Any Devices with Poor or Marginal Corrosion Resistance
- •Nitinol devices with poor fatigue resistance
- Any device with poor fatigue resistance

^{*}reflects the option to select multiple scenarios

HW: If you perform nickel leach testing, please indicate the alloy and device type:





Methods for in vitro nickel leach testing

Parameters that were co	onsistent across	all responses	(n=8):
-------------------------	------------------	---------------	--------

Finished Sterilized Device Yes

Temperature 37 degrees C

External Mechanical Loading No

Open Circuit Potential No*

Quantitative Parameters that are varied across all responses


Duration (days; min, max, median) (n=9)


Surface Area Ratio (cm²/ml; min, max, median) (n=4) 0.1, 6, 0.6


Resolution (µg/ml [ppm]; min, max, median) (n=8) 0.0005, 0.05, 0.00175

3,90,30

Sampling Time Points (n=8 responses)









N=10

Containers:


PFE Tubes


- iChem certified vial
- Borosilicate Glass Container
- PFA Containers





N=9





N=9

HW: How much nickel do you typically see being released from your device(s) in vitro?

For nitinol devices:


Device Surface Area (min max, median)	0.9, 50.13, 5.3 cm ²	n=8
Minimum peak release rate (range)	0.19-2.89 μg/day	n=5
Maximum Peak release rate (range)	0.42-8.40 μg/day	n=5
Average peak release rate (range)	0.043-4.8 μg/day	n=7
Time to Peak release (min, max, median)	<1, 30, 3.5 days	n=12
Peak release acceptance criteria (range)	35-670 μg/day	n=6
Minimum chronic release rate (range)	<0.015-0.63 μg/day	n=7
Maximum chronic release rate (range)	<0.015-1.72 μg/day	n=7
Average chronic release rate (range)	<0.015-1.31 μg/day	n=7
Minimum Total Release (range)	2.0-80 μg	n=6
Maximum Total Release (range)	5.13-140 μg	n=6
Average Total Release (range)	0.11-110 μg	n=9

Objective 2: Discuss in vitro nickel leach testing

- Discuss best practices (30 min)
 - What are appropriate sampling frequencies and test duration?
 - Does choice of immersion medium matter?
 - How should the possibility of adsorption and precipitation be mitigated?
 - Other?
- Discuss significance of peak vs. total release (10 min)
- Discuss the limitations of in vitro testing (10 min)

Objective 3: Discuss in vitro/in vivo nickel release correlation (60 min)

HW: Do you perform in vivo nickel release assessments?



Objective 3: Discuss in vitro – in vivo correlation of nickel release and patient exposure

 Talk on in vivo nickel release in patients with cardiovascular occlusion devices (Joyce Tsuji, Exponent; 20 min)

Discuss in vivo nickel release in patients (10 min)

Objective 3: Discuss in vivo nickel release assessment

 Discuss what has been learned from in vivo nickel leach testing in literature (10 min)

 Discuss animal and clinical approaches to evaluate nickel release (10 min)

Discuss the limitations of in vivo nickel assessment (10 min)

Objective 4: Discuss toxicity associated with levels of nickel exposure (60 min)

 Talk on data for toxicity analysis (Ron Brown, FDA; 60 min)

Objective 5: Moving Forward: Identify knowledge gaps (30 min)

- Is the current testing paradigm sufficient to assess nickel release and toxicity?
- What form of nickel is released from medical devices?
- How do you assess nickel toxicity given that there are biological effects of combinations of nickel with other substances?
- Can you extrapolate data and methods from adult populations to develop a pediatric TI?